DuPont de Nemours, Inc. · NYSE:DD

DuPont de Nemours — DuPont — Technical Presentation (October 2014)

46 slides from DuPont de Nemours's technical presentation, Oct 2, 2014

  1. Slide 1: The Results Are In — First Industry Summary Report

    The Results Are In — First Industry Summary Report October 2, 2014

  2. Slide 2: Presenters

    Presenters Bruce A. Yost, Ph.D. Global Technical Director Michael H. Scholla, Ph.D. Global Regulatory Director Leslie Love North America MDM Specialist 2

  3. Slide 3: Today's Bottom Line

    Today’s Bottom Line ! Pre- and post-sterilization package results to date continue to indicate functional equivalence ! U.S. FDA affirmation of functional equivalence is expected 3Q 2015 ! Guidance received from regulatory authorities in Japan, China and Canada and from six Notified Bodies in Europe

  4. Slide 4: What You're Going To Hear Today

    What You’re Going To Hear Today ! MPTP Package Testing Results — First Complete Summary Report ! Regulatory and Timeline Updates ! Information Available to Help You Be Ready Expect U.S. FDA to affirm functional equivalence 3Q 2015 4

  5. Slide 5: DuPont and Industry Collaborative Cast of Thousands

    DuPont and Industry Collaborative Cast of Thousands 5

  6. Slide 6: Publication of MPTP Test Results

    Technical Publication of MPTP Test Results Timing 1A—Pre-sterilization and Post-sterilization, t=0, Initial Results May 2014 1B—Pre-sterilization and Post-sterilization, t=0, Final Results TODAY! 2—Accelerated Aging (1, 3 and 5 Years) Real-time Aging (1 Year) PARTIAL TODAY! Additional Accelerated Ag

  7. Slide 7: U.S. FDA Transition Protocol Test Matrix — Nelson Laboratories Testing Status

    Technical U.S. FDA Transition Protocol Test Matrix — Nelson Laboratories Testing Status (as of September 10, 2014) 7

  8. Slide 8: Phantom Protocol Test Matrix — Nelson Laboratories Testing Status

    Technical Phantom Protocol Test Matrix — Nelson Laboratories Testing Status (as of September 10, 2014) 8

  9. Slide 9: MPTP Data Statistically Analyzed at This Time

    Technical MPTP Data Statistically Analyzed at This Time 114,729 Package visual inspections — ASTM F1886M 53,664 Seal strength measurements — ASTM F88 9,522 Package integrity tests — ASTM F1929 1,302 Microbial barrier tests — ASTM F2638 And, still counting! 9

  10. Slide 10: Pre- & Post-Sterilization Visual Inspection Summary — ASTM F1886M

    Technical Pre- & Post-Sterilization Visual Inspection Summary — ASTM F1886M 10

  11. Slide 11: Pre- & Post-Sterilization Package Integrity Summary — ASTM F1929

    Technical Pre- & Post-Sterilization Package Integrity Summary — ASTM F1929 11

  12. Slide 12: Pre- & Post-Sterilization Microbial Barrier Summary — ASTM F2638

    Technical Pre- & Post-Sterilization Microbial Barrier Summary for 1073B and 1059B — ASTM F2638 12

  13. Slide 13: Pass/Fail Summary for Seal Strength — ASTM F88

    Technical Industry Summary: MPTP Test Results at Pre- & Post-Sterilization, Pass/Fail Summary for Seal Strength* — ASTM F88 13

  14. Slide 14: Footnotes and Comment on Seal Strength Summary Table

    Technical Footnotes and Comment on Pre- & Post-Sterilization Seal Strength Summary Table *Vent bag, Kwikbreathe™ True Header bag and weld seal bag seal strengths are not included; the failure modes were non-peelable seals. **A high sealing condition for one package configuration exceeded the high en

  15. Slide 15: Driver for Root Cause Failure Analysis of Seal Strength Anomaly

    Technical Driver for Root Cause Failure Analysis (RCFA) of Seal Strength Anomaly 15

  16. Slide 16: Percent Change in Seal Strength for Maximum Load — ASTM F88

    Technical Percent Change in Seal Strength Relative to the Control for Maximum Load — ASTM F88 16

  17. Slide 17: Percent Change in Seal Strength for Average Load — ASTM F88

    Technical Percent Change in Seal Strength Relative to the Control for Average Load — ASTM F88 17

  18. Slide 18: Seal Strength Change for Coated and Uncoated 1073B Cells

    Technical Percent Change in Seal Strength Relative to the Control for Coated and Uncoated 1073B Cells — ASTM F88 18

  19. Slide 19: Seal Strength Change for Coated 1073B Lids/Rigid Trays

    Technical Percent Change in Seal Strength Relative to the Control for Coated 1073B Lids/Rigid Trays — ASTM F88 19

  20. Slide 20: 1-Year Accelerated Aging Package Integrity Summary — ASTM F1929

    Technical 1-Year Accelerated Aging Package Integrity Summary for 52 Cells — ASTM F1929 20

  21. Slide 21: 1-Year Accelerated Aging Microbial Barrier Summary — ASTM F2638

    Technical 1-Year Accelerated Aging Microbial Barrier Summary for 52 Cells — ASTM F2638 21

  22. Slide 22: 1-Year Accelerated Aging Pass/Fail Summary for Seal Strength

    Technical Industry Summary: MPTP 52 Cell Test Results at 1-Year Accelerated Aging, Pass/Fail Summary for Seal Strength — ASTM F88 22

  23. Slide 23: Seal Strength Change, Maximum Load, 1-Year Accelerated Aging

    Technical Percent Change in Seal Strength Relative to the Control for Maximum Load at 1-Year Accelerated Aging — ASTM F88 23

  24. Slide 24: Seal Strength Change, Average Load, 1-Year Accelerated Aging

    Technical Percent Change in Seal Strength Relative to the Control for Average Load at 1-Year Accelerated Aging — ASTM F88 24

  25. Slide 25: NEW Transition Protocol Material Data

    Technical NEW Transition Protocol Material Data ! Effects of sterilization and 3-year accelerated aging on: -- material puncture strength -- material tensile strength -- material microbial barrier (ASTM F2638) ! Effects of sterilization on material microbial barrier (ASTM F1608) 25

  26. Slide 26: Sterilization and Aging Effects on Material Puncture Strength for 1073B

    Technical Effects of Sterilization and 1- and 3-Year Accelerated Aging on Material Puncture Strength for 1073B 26

  27. Slide 27: Sterilization and Aging Effects on Material Microbial Barrier for 1073B

    Technical Effects of Sterilization and 1- and 3-Year Accelerated Aging on Material Microbial Barrier for 1073B — ASTM F2638 27

  28. Slide 28: Effects of Sterilization on Material Microbial Barrier for 1073B — ASTM F1608

    Technical Effects of Sterilization on Material Microbial Barrier for 1073B — ASTM F1608 28

  29. Slide 29: Additional Data Generated Per Industry Requests

    Technical Additional Data Generated Per Industry Requests Available on our website: ! Particle generation ! Steam and low-temperature oxidative sterilization behaviors ! Dimensional stability study (steam–freeze–thaw–freeze–thaw) ! DSC, FTIR NEW on our website: ! Dynamic/static coefficient of fricti

  30. Slide 30: Publication of MPTP Test Results

    Technical Publication of MPTP Test Results Timing 1A—Pre-sterilization and Post-sterilization, t=0, Initial Results May 2014 1B—Pre-sterilization and Post-sterilization, t=0, Final Results TODAY! 2—Accelerated Aging (1, 3 and 5 Years) Real-time Aging (1 Year) PARTIAL TODAY! Additional Accelerated Ag

  31. Slide 31: Global Members of the DuPont Medical and Pharmaceutical Protection Regulatory Team

    Global Members of the DuPont Medical and Pharmaceutical Protection Regulatory Team Michael H. Scholla, Ph.D. Thierry Wagner Ichiro Ikeda Park J. Qian Jane E. Severin, Ph.D., CPP Global Regulatory Director EMEA Regulatory Director Asian Regulatory Director Regulatory Affairs Manager, North America Ch

  32. Slide 32: Regulatory Guidance

    Regulatory Regulatory Guidance Documents available on our website: ! Guidance from U.S. FDA -- March 1, 2011 -- October 18, 2012 ! Guidance from Japan -- September 19, 2012 -- September 25, 2013 ! Summary of guidance from China, CFDA-Jinan ! Guidance from Health Canada ! Guidance from European Notif

  33. Slide 33: Regulatory Guidance Letter from DQS Medizinprodukte GmbH

    ‘egulatory DQS Medizinprodukte GmbH DQsS, | MED To whom it may concer, Frankfurt a. MA 09.09.2014 DuPont Medical and Pharmaceutical Packaging will be transitioning Tyvek® 10738, ‘and 10598 styles for medical packaging applications to manufacturing lines using the latest Tyvek® manufacturing technolo

  34. Slide 34: DuPont Medical and Pharmaceutical Protection — Global MDM Support Team

    DuPont Medical and Pharmaceutical Protection — Global MDM Support Team Leslie Love Jose Arevalo Karen Polkinghorne Nicole Kaller Helmut Scheckenbach North America North America and North America EMEA EMEA Central America Eric Schmohl Joong Siong Bong Coy Li Norihiko Matsuda EMEA ASEAN China Japan 34

  35. Slide 35: MPTP Milestones

    MPTP Milestones 1 M 2 Developmental Developmental Material Creation Material Testing and Industry Evaluation 7 M 8 MPTP Package Phantom Protocol Creation and Testing Sterilization Regulatory Milestones M Mw U.S. FDA Transition Guidance Received Protocol Reviewed from Six Notified and Accepted by Bod

  36. Slide 36: The Time to Get Ready Is Now

    Commercialization The Time to Get Ready Is Now ! What can MDMs do to be ready? • Proceed with your change management process, including risk assessments and associated documentation • Use controlled sales material to complete any additional testing as determined by your own risk assessments • Ensure

  37. Slide 37: Coming Soon — New MPTP Package Test Results Selector Tool

    Commercialization Coming Soon — New MPTP Package Test Results Selector Tool 37

  38. Slide 38: Coming Soon — New App for Mobile Devices

    Commercialization Coming Soon — New App for Mobile Devices 38

  39. Slide 39: www.areyouready.tyvek.com

    Commercialization www.areyouready.tyvek.com What’s New: ! MPTP pre- and post-sterilization package data ! 1-Year accelerated aging package data ! 3-Year accelerated aging material data ! Dynamic/static coefficient of friction data ! Parker (surface) smoothness data ! Surface energy data ! Guidance f

  40. Slide 40: Other Ways to Stay Informed

    Commercialization Other Ways to Stay Informed ! www.transition.tyvek.com ! www.areyouready.tyvek.com ! Global webcasts – live or available on-demand for up to a year ! Frequently Asked Questions Document ! Tyvek® Rx eNewsletter ! Face-to-face seminars ! Trade and technical forums ! Individual meetin

  41. Slide 41: Today's Bottom Line

    Today’s Bottom Line ! Pre- and post-sterilization package results to date continue to indicate functional equivalence ! U.S. FDA affirmation of functional equivalence is expected 3Q 2015 ! Guidance received from regulatory authorities in Japan, China and Canada and from six Notified Bodies in Europe

  42. Slide 42: Mark Your Calendars

    Mark Your Calendars ! DuPont Seminar at Michigan State University—October 9 ! DuPont Seminar in the Dominican Republic—To be rescheduled 1Q 2015 ! Next global webcast—November 13—more interactive discussion on functional equivalence and material interchangeability ! Meet the DuPont team of experts a

  43. Slide 43: A Note of Appreciation

    A Note of Appreciation ! Thank you for your business, your continued support and your confidence in DuPont ! We are committed to support you throughout this transition ! Together, we can continue to meet the needs of a growing population for safe and sustainable medical packaging www.transition.tyve

  44. Slide 44: Questions?

    Questions? www.transition.tyvek.com www.areyouready.tyvek.com 44

  45. Slide 45: Thank you!

    Thank you! Thank you for attending today’s Webcast: The Results Are In — First Industry Summary Report Today’s webcast will be archived for one year for on-demand viewing within this environment. For any additional questions, please contact us: Daphne Allen, Editor, Pharmaceutical & Medical Packagin

  46. Slide 46: Copyright © 2014 DuPont. All rights reserved.

    Copyright © 2014 DuPont. All rights reserved. The DuPont Oval Logo, DuPont™ and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. 46

DuPont — Technical Presentation (October 2014) on 6ix